J Patzelt1, K A L Mueller2, S Breuning2, A Karathanos2, R Schleicher3, P Seizer2, M Gawaz2, H F Langer4, T Geisler5. 1. Section for Cardioimmunology, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany; University Hospital, Department of Cardiovascular Medicine, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany. 2. University Hospital, Department of Cardiovascular Medicine, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany. 3. Section for Cardioimmunology, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany. 4. Section for Cardioimmunology, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany; University Hospital, Department of Cardiovascular Medicine, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany. Electronic address: harald.langer@med.uni-tuebingen.deor. 5. University Hospital, Department of Cardiovascular Medicine, Eberhard-Karls University Tuebingen, 72076 Tuebingen, Germany. Electronic address: tobias.geisler@med.uni-tuebingen.de.
Abstract
OBJECTIVE: Inhibition of components of the complement system or of its receptors has been postulated as a concept for primary and secondary prevention in atherosclerosis and was applied in clinical trials. Although the anaphylatoxin-receptors C3aR and C5aR are commonly associated with inflammatory cells, in vitro studies suggested their expression also on platelets. METHODS AND RESULTS: Expression levels of C3aR and C5aR were measured by flow cytometry in a collective of 302 patients with documented coronary artery disease (CAD) including patients with stable CAD (n = 152), unstable angina (n = 54), acute myocardial infarction (AMI; Non-ST elevation myocardial infarction, n = 70, ST elevation MI, n = 26) or healthy controls (n = 21). Patients with stable CAD, unstable angina or AMI had significantly higher expression of C5aR on platelets in comparison to healthy controls (MFI 14.68 (5.2), 14.56 (5.18) and 13.34 (4.52) versus 10.68 (3.1)); p < 0.001). In contrast, the expression of C3aR on platelets was significantly enhanced in patients with stable and unstable CAD but not in patients with AMI compared to controls. While there was a strong correlation between the soluble ligands of these receptors C3a and C5a, we observed only a weak correlation with their receptors on platelets. Similarly, agonist induced aggregation (MEA, ADP, and TRAP) showed only a weak correlation with the expression level of anaphylatoxin - receptors on platelets. Of note, the expression of both anaphylatoxin-receptors on platelets strongly correlated with platelet activation as assessed with the surface activation marker P-selectin (r = 0.47, p > 0.001 for C3aR, r = 0.76 for C5aR, p < 0.001). Likewise, we observed a positive correlation of C3aR with other molecules associated with platelet activation such as SDF-1. CONCLUSION: In summary, we observed a positive correlation between the expression of anaphylatoxin-receptors C3aR and C5aR with platelet activation in patients with CAD. Further investigations are needed to study the clinical and mechanistic relevance of these findings.
OBJECTIVE: Inhibition of components of the complement system or of its receptors has been postulated as a concept for primary and secondary prevention in atherosclerosis and was applied in clinical trials. Although the anaphylatoxin-receptors C3aR and C5aR are commonly associated with inflammatory cells, in vitro studies suggested their expression also on platelets. METHODS AND RESULTS: Expression levels of C3aR and C5aR were measured by flow cytometry in a collective of 302 patients with documented coronary artery disease (CAD) including patients with stable CAD (n = 152), unstable angina (n = 54), acute myocardial infarction (AMI; Non-ST elevation myocardial infarction, n = 70, ST elevation MI, n = 26) or healthy controls (n = 21). Patients with stable CAD, unstable angina or AMI had significantly higher expression of C5aR on platelets in comparison to healthy controls (MFI 14.68 (5.2), 14.56 (5.18) and 13.34 (4.52) versus 10.68 (3.1)); p < 0.001). In contrast, the expression of C3aR on platelets was significantly enhanced in patients with stable and unstable CAD but not in patients with AMI compared to controls. While there was a strong correlation between the soluble ligands of these receptors C3a and C5a, we observed only a weak correlation with their receptors on platelets. Similarly, agonist induced aggregation (MEA, ADP, and TRAP) showed only a weak correlation with the expression level of anaphylatoxin - receptors on platelets. Of note, the expression of both anaphylatoxin-receptors on platelets strongly correlated with platelet activation as assessed with the surface activation marker P-selectin (r = 0.47, p > 0.001 for C3aR, r = 0.76 for C5aR, p < 0.001). Likewise, we observed a positive correlation of C3aR with other molecules associated with platelet activation such as SDF-1. CONCLUSION: In summary, we observed a positive correlation between the expression of anaphylatoxin-receptors C3aR and C5aR with platelet activation in patients with CAD. Further investigations are needed to study the clinical and mechanistic relevance of these findings.
Authors: Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Armugam P Mekala; Petru A Mircea; Florin Niculescu; Horea Rus Journal: Immunol Res Date: 2016-02 Impact factor: 2.829
Authors: Caroline S Gravastrand; Bjørg Steinkjer; Bente Halvorsen; Anne Landsem; Mona Skjelland; Eva Astrid Jacobsen; Trent M Woodruff; John D Lambris; Tom E Mollnes; Ole-Lars Brekke; Terje Espevik; Anne Mari A Rokstad Journal: J Immunol Date: 2019-07-03 Impact factor: 5.422
Authors: Sokratis A Apostolidis; Amrita Sarkar; Heather M Giannini; Rishi R Goel; Divij Mathew; Aae Suzuki; Amy E Baxter; Allison R Greenplate; Cécile Alanio; Mohamed Abdel-Hakeem; Derek A Oldridge; Josephine Giles; Jennifer E Wu; Zeyu Chen; Yinghui Jane Huang; Ajinkya Pattekar; Sasikanth Manne; Oliva Kuthuru; Jeanette Dougherty; Brittany Weiderhold; Ariel R Weisman; Caroline A G Ittner; Sigrid Gouma; Debora Dunbar; Ian Frank; Alexander C Huang; Laura A Vella; John P Reilly; Scott E Hensley; Lubica Rauova; Liang Zhao; Nuala J Meyer; Mortimer Poncz; Charles S Abrams; E John Wherry Journal: bioRxiv Date: 2021-05-03
Authors: Jason M Samuels; Julia R Coleman; Ernest E Moore; Matt Bartley; Navin Vigneshwar; Mitchell Cohen; Christopher C Silliman; Angela Sauaia; Anirban Banerjee Journal: Shock Date: 2020-05 Impact factor: 3.533
Authors: Jessica Kristin Henes; Patrick Groga-Bada; Elke Schaeffeler; Stefan Winter; Luis Hack; Monika Zdanyte; Karin Mueller; Michal Droppa; Fabian Stimpfle; Meinrad Gawaz; Harald Langer; Matthias Schwab; Tobias Geisler; Dominik Rath Journal: Pharmgenomics Pers Med Date: 2021-07-21